Poposka, Lidija
Preferred name
Poposka, Lidija
Official Name
Poposka, Lidija
Main Affiliation
Email
lidija.poposka@medf.ukim.edu.mk
68 results
Now showing 1 - 10 of 68
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry(Wiley, 2022-06) - Some of the metrics are blocked by yourconsent settings
Item type:Publication, P1495ECG parameters as predictors of response to cardiac resynchronization therapy(Oxford University Press (OUP), 2017-06); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, IMPORTANCE OF ADDITIONAL ECHOCARDIOGRAPHIC PARAMETERS IN SELECTING A CRT RESPONDER PATIENT(Wiley, 2013-05); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cardiac memory (t-wave memory) after ablation of posteroseptal accessory pathway(2008-07); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Secondary Thromboprophylaxis in Hereditary Thrombophilia(SCIENCEDOMAIN International, 2018-02); ; ; Aims: The aim of this study is to show how the coagulation laboratory and clinical findings worked together in the management of a patient with hereditary thrombophilia and pulmonary embolism (PE) in terms of diagnosis, the choice of anticoagulation treatment and the duration of secondary thromboprophylaxis. Study Design: A case report with the presentation of clinical and laboratory findings, treatment and long-term follow up of the patient. Place and Duration of Study: Institute of Transfusion Medicine and University Clinics of Cardiology, St Cyril and Methodius University, Skopje, Macedonia in the period from February 2015 and December 2017. Case Presentation: Computer tomography confirmed the diagnosis of PE in a 32-year-old man who was admitted to the cardiology emergency department with D-dimer level of 5980 ng/mL after an episode of syncope. After the initial anticoagulation with unfractionated heparin 30.000i.e./24 h,enoxaparin 80 mg/12 h and acenocoumarol were introduced. The therapeutic INR rang could not be achieved so the acenocoumarol was switched to rivaroxaban 2x15 mg/day. One year later the anticoagulation with rivaroxaban 20 mg/day was discontinued. Thrombophilia testing included: prothrombin (PTB), Factor V Leiden and methylene tetrahydrofolate reductase (MTHFR) C677T gene mutation, as well as antiphospholipid antibodies, antithrombin, protein C and S. Results: The patient was homozygous for the PTB. His parents were heterozygous for the same mutation; his mother also being heterozygous for MTHFR C677T. His brother was compound heterozygote for PTB and MTHFR C677T and his sister was heterozygous for the PTB. Coagulation status monitoring showed hypercoagulability (APTT was 24-26 seconds) and increment of D-dimer (2100-2400 ng/ml) when rivaroxaban was discontinued and normal APTT (28-38 seconds) and Ddimer (< 500 ng/mL) when it was reintroduced. Conclusion: According to the laboratory findings and also having in mind that this was a second episode of a thrombotic event, we decided for an extended secondary thromboprophylaxis. Although it sometimes implies that it will be continued life-long we consider worthwhile to apply the patientoriented approach to the decision when and whether to terminate anticoagulation. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Correlating the Cholesterol Levels to Glucose for Men and Women(Ss. Cyril and Methodius University in Skopje, Faculty of Computer Science and Engineering, Republic of North Macedonia, 2020-05-08); ; Objectives: This paper explores the correlation between multiple cholesterol levels of the lipid profiles of patients and their diabetes regulation abilities in men and women. Methodology: The methodology includes the following techniques: i) Pearson correlation ii) Spearman rank correlation and iii) setting thresholds for certainty of class assumption. Data: The methods were applied on data from 161 patients of which 110 male and 41 female, analyzing the variables about patients’ age, height, weight, BMI, lipid profile (total cholesterol, HDL cholesterol, LDL cholesterol, triglycerides), glycated hemoglobin levels with respective glucose regulation and diabetes classes, history of heart, diabetes and other chronic illnesses, habitual behaviors (smoking, alcohol consumption, physical activity), and medications intake (calcium channel blockers, BETA blockers, anti-arrhythmics, AKE/ARB inhibitors, diuretics, statins anti-aggregation medication and anticoagulants). Conclusion: Analyzing the correlations between the lipid profile and glucose regulation in patients led to different results when the analysis was done separately on men and women. Thus, better predictions and insights can be made dependent on gender. The research found no strong stand-alone correlation when analyzing all data, but when the data was segmented in male and female records, a strong negative linear (r=-0.52, p=0.001) and non-linear (r=-0.55, p=0.001) correlation was found for the HDL-C and glucose levels in female patients. In men, statistically significant negative correlations with HbA1c were assessed for Chol (r=-0.27, p=0.009), LDL-C (r=-0.33, p=0.002) and HDL-C (r=-0.23, p=0.026). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, First Macedonian Registry on Atrial Fibrillation(Hrvatsko kardiološko društvo, 2013-09-23); ; ; Objectives: More than a half of the patients with atrial fibrillation (AF) are not adequately anti-coagulated, even though there is strong evidence in favor of the oral anticoagulant (OAC) therapy used in prevention of ischemic stroke in this patient-population. Most frequent factors causing this problem are: non-adherence to the Guidelines as well as the limitations like: difficulties in the maintenance of INR within therapeutic range, the necessity of monitoring and numerous interactions with food and other medications. Aim: Concerning non-adherence to the Guidelines all over the world in the treatment of the patients with AF, the aim of this Registry is to find the weak points in the treatment of these patients, and equilibrate the treatment all over the Country. Patients and Methods: More than 1,000 consecutive patients with AF in their electrocardiogram, diagnosed in the last year will be included in this Registry in the first year, from all over the country. All parameters concerning underlying cardiovascular disease will be listed and analyzed, also all co-morbidities. All diagnostic and interventional procedures, medications during this period will be analyzed, with special concern on anticoagulation therapy, type of anticoagulation, monitoring, and reason why, if not anti-coagulated. Analyses will be done in the way of treatment of the patient regarding the place of consultation: outpatient department, hospital, university clinic. Outcome points were defined as: cardiovascular death, death from other reason, ischaemic stroke, hemorrhagic stroke, transitory ischaemic attack, other major hemorrhage or thrombo-embolic complication. Results: Will be available at the end of the study; preliminary results will be due July 2013. Conclusion: General risk profile of patients with AF, frequency of anticoagulation, frequency of effective treatment and risks of bleeding will be evaluated. All outcome points will be analyzed, their independent predictors will be determined and the follow up will continue in the next 5 years. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Trends from Minimally Invasive to Non-invasive Glucose Measurements(IEEE, 2020-09-28); ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Correlating Glucose Regulation with Lipid Profile(Springer International Publishing, 2020); ; Objectives: The goal of this research was to detect the glucose regulation class by evaluating the correlation between the lipid profile of patients and their glucose regulation class. Methodology: The methods used in this research are: i) Point Biserial Correlation, ii) Univariate Logistic Regression iii) Multivariate Logistic Regression iv) Pearson Correlation and v) Spearman Rank correlation. Data: The dataset consists of the following features: age, BMI, gender, weight, height, total cholesterol (Chol), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), triglycerides (TG), glycated hemoglobin (HbA1C), glucose regulation and diabetes classes, history of diabetes, heart and other chronic illnesses, habitual behaviors (smoking, alcohol consumption, physical activity), and medications intake (calcium channel blockers, BETA blockers, anti-arrhythmic, AKE/ARB inhibitors, diuretics, statins anti-aggregation medication and anticoagulants). Conclusion: The methodologies that were worked through with our data in search for correlations of the lipid profile with HbA1c or the glucose regulation classes gave some significant correlations. Regarding the glucose regulation classes W and B the methods showed statistically significant negative correlations with Chol, HDL-C and LDL-C. When it comes to the correlations of the lipid profile with HbA1c, for all patients there were significant negative correlations with Chol (corr = −0.264, p = 0.002), LDL-C (corr = −0.297, p < 0.001) and HDL-C (corr = −0.28, p = 0.001) and a significant positive correlation with TG (corr = 0.178, p = 0.03). The correlations mentioned are the stronger ones that were found for linear relationships. For non-diabetic patients there was a stronger positive non-linear correlation for HbA1c and HDL-C (corr = 0.511, p = 0.006), and a slightly weaker linear correlation (corr = 0.393, p = 0.043). For prediabetic patients there were no significant correlations. For type 2 diabetes stronger significant negative non-linear correlations were found for HbA1c with LDL-C (corr = −0.299, p = 0.023) and HDL-C (corr = −0.438, p = 0.001). The linear relationships were again, slightly weaker with LDL-C (corr = −0.273, p = 0.038) and with HDL-C (corr = −0.391, p = 0.002). - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Outcomes of digoxin vs. beta blocker in atrial fibrillation: report from ESC–EHRA EORP AF Long-Term General Registry(Oxford University Press (OUP), 2021-10-19)